ARTIFICIAL INTELLIGENCE
3B Biotech Research collaborates with qualified partners mastering technological and software solutions for the application of Artificial Intelligence
Artificial Intelligence (AI) can be currently described as "a set of different technologies that interact to allow machines to perceive, understand, act and learn with level of intelligence similar to human one"
Two kinds of Artificial Intelligence can be distinguished:
- NARROW or WEAK AI: specifically designed to be focused on a narrow task in a specific area, relating to individual tasks that are often very consequential. The primary objective, in this type of applications, is to increase the efficiency of all processes;
- STRONG AI: a certain mindset of artificial intelligence development. Strong AI’s goal is to develop artificial intelligence to the point where the machine’s intellectual capability is functionally equal to a human’s, systems capable of “thinking” in a strategic, abstract and creative way, “with the ability to manage a series of complex tasks
Artificial intelligence, for example, allows for the consolidation of data assets from clinical studies and beyond, helping researchers to identify models and draw conclusions. It also offers the ability to collaborate, analyze information and focus on insights allowing you to make life-saving discoveries.
In particular, new methods of data analysis can increase the ability of physicians to interpret and act on complex and large data sets.
Technology plays an important role today in improving outcomes, increasing safety and reducing healthcare costs.
Supportive devices such as reminders, alerts and clinical data directly derived from electronic health records will guide the physician’s decision-making process. In this clinical scenario, physicians and managers should apply, in practice, technology validated by companies offering artificial intelligence software to assist physicians in disease diagnosis and treatment algorithms.
It is important to underline the important contribution that artificial intelligence is offering to pharmacological and biomedical researchers, allowing analyses and forecasts that were unimaginable up to the last decade.